3 years ago

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed and refractory non-Hodgkin lymphoma.

Pisal, González Barca, Gerecitano, Bociek, Tavorath, Kong, Salles, Kim, Turgut, Younes, Caballero Barrigon, Martinelli
Phosphatidylinositol 3-kinase mechanistic target of rapamycin pathway activation plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label Phase II study evaluated buparlisib (BKM120), a pan-class I Phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. Patients received buparlisib 100 mg once daily in three separate cohorts (diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) until progression, intolerance, or withdrawal of consent. The primary endpoint was overall response rate based on a 6-month best overall response by cohort; secondary endpoints included progression-free survival, duration of response, overall survival, safety, and tolerability. Overall, 72 patients (diffuse large B-cell lymphoma [n=26], mantle cell lymphoma [n=22], and follicular lymphoma [n=24]) were treated. The overall response rate was 11.5%, 22.7%, and 25.0% in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, respectively; two patients (one each in diffuse large B-cell lymphoma and mantle cell lymphoma cohorts) achieved a complete response. The most frequently reported (>20%) any-grade adverse events in the safety population were hyperglycemia, fatigue, and nausea (36.1% each), depression (29.2%), diarrhea (27.8%), and anxiety (25.0%). The most common grade 3/4 AEs included hyperglycemia (11.1%) and neutropenia (5.6%). Buparlisib showed activity in non-Hodgkin lymphoma, with disease stabilization and sustained tumor burden reduction in some patients with relapsed or refractory non-Hodgkin lymphoma, and acceptable toxicity. Development of mechanism-based combination regimens with buparlisib is warranted. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT01693614).

Publisher URL: http://doi.org/10.3324/haematol.2017.169656

DOI: 10.3324/haematol.2017.169656

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.